Cue Biopharma
Peter Sheridan has over 16 years of work experience in the biopharmaceutical industry. Peter began their career in 2005 as a Senior Manager at Amgen Inc. In 2008, they moved to Genzyme Biosurgery as an Associate Director of Quality Control. In 2009, they became a Director of Quality Control at Alexion Pharmaceuticals. In 2015, they were promoted to Director of Quality at Keryx Biopharmaceuticals. In 2018, they were promoted to Senior Director and Head of Quality at Ra Pharmaceuticals. In 2020, they moved to UCB-Ra Pharma as the Head of Development Quality. Most recently, in 2021, they joined Cue Biopharma as the Senior Director and Head of Quality and Regulatory.
Peter Sheridan has attended UMass Boston.
Cue Biopharma
1 followers
Cue Biopharma is an innovative immunotherapy company dedicated to developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat a broad range of cancers and autoimmune disorders. Cue Biopharma’s Immuno-STAT Biologics are designed to engage directly with and modulate the activity of disease-associated T cells in the patient’s body, potentially offering significant therapeutic advantages while minimizing or eliminating unwanted side effects.